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Abstract
Background: The kidneys are essential for the metabolism of vitamin A (retinol) and its transport proteins retinol-
binding protein 4 (RBP4) and transthyretin. Little is known about changes in serum concentration after living donor
kidney transplantation (LDKT) as a consequence of unilateral nephrectomy; although an association of these
parameters with the risk of cardiovascular diseases and insulin resistance has been suggested. Therefore we
analyzed the concentration of retinol, RBP4, apoRBP4 and transthyretin in serum of 20 living-kidney donors and
respective recipients at baseline as well as 6 weeks and 6 months after LDKT.
Results: As a consequence of LDKT, the kidney function of recipients was improved while the kidney function of
donors was moderately reduced within 6 weeks after LDKT. With regard to vitamin A metabolism, the recipients
revealed higher levels of retinol, RBP4, transthyretin and apoRBP4 before LDKT in comparison to donors. After
LDKT, the levels of all four parameters decreased in serum of the recipients, while retinol, RBP4 as well as apoRBP4
serum levels of donors increased and remained increased during the follow-up period of 6 months.
Conclusion: LDKT is generally regarded as beneficial for allograft recipients and not particularly detrimental for the
donors. However, it could be demonstrated in this study that a moderate reduction of kidney function by
unilateral nephrectomy, resulted in an imbalance of components of vitamin A metabolism with a significant
increase of retinol and RBP4 and apoRBP4 concentration in serum of donors.
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Background
Kidney transplantation is increasingly performed by liv-
ing donation. Living donor kidney transplantation
(LDKT) provides superior allograft function for the reci-
pients [1] with a low risk of complications such as
hypertension and chronic kidney disease (CKD) for
donors. However, unilateral nephrectomy leads to a
reduction of the donor’s glomerular filtration rate (GFR)
[2,3], which could result in altered renal clearance and
catabolism of many substances, thereby potentially
increasing the risk for metabolic disturbances after
LDKT. Such metabolic disturbances could mediate an
increased risk for cardiovascular disease (CVD), which is
present even in early stages of CKD [4]. Among the sub-
stances with altered renal clearance are the compounds
of the vitamin A transport complex, namely retinol
(ROH), retinol-binding protein 4 (RBP4) and transthyre-
tin (TTR). ROH represents the transport form of vita-
min A and is specifically transported by RBP4 in the
circulation. Furthermore, the ROH-RBP4 complex is
non-covalently linked to the visceral protein TTR [5].
T h ek i d n e y sa r ei m p o r t a n tf or metabolism and catabo-
l i s mo fR O H ,R B P 4a n dT T R[ 5 - 7 ]a n ds e r u mc o n c e n -
trations of all three metabolites are increased in patients
with reduced kidney function [8,9]. Especially RBP4
serum concentration has been shown to be closely asso-
ciated with GFR in a reverse fashion [10,11]. Vitamin A
is essential for numerous biological functions such as
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any medium, provided the original work is properly cited.vision, cellular differentiation and immune defense [7].
However, elevated ROH as well as RBP4 serum concen-
trations have been associated with an increased risk of
CVD [12-15]. Additionally, high levels of RBP4 have
been linked to the development of insulin resistance
[16]. Therefore, increased ROH and RBP4 serum con-
centrations in donors may increase their risk of CVD
and insulin resistance post-nephrectomy.
Since very little is known so far about changes of ROH,
RBP4 and TTR serum concentrations in kidney donors,
the aim of the present study was to determine the
changes of all three substances before and after trans-
plantation in serum of donors and recipients as well as
their association to estimated GFR (eGFR). Additionally,
the relative amount of circulating apoRBP4 (RBP4 free
from ROH) was determined, since apoRBP4 represents a
physiologic signal for an increased hepatic holoRBP4
(RBP4 with ROH) secretion, which could theoretically
lead to further increase of ROH and RBP4 concentra-
tions. The results of this study may contribute to future
cardiovascular risk assessments in living donors.
Results
Comparison of clinical parameters of transplant donors
and recipients
The clinical parameters of allograft donors and recipients
a tb a s e l i n ea sw e l la s6w e e k sa n d6m o n t h sa f t e rL D K T
are presented in Table 1. The age presented in Table 1 is
the median age of donors (46 years) and recipients (42
years) at baseline and did not differ between both groups.
At baseline, allograft recipients revealed significantly
lower estimated GFR (eGFR, p < 0.001) in comparison
to living-kidney donors. However, eGFR did not differ 6
weeks and 6 months after LDKT, respectively. Addition-
ally, proteinuria was significantly higher in recipients
than in donors at baseline (p < 0.001) as well as 6 weeks
(p = 0.018) and 6 months (p = 0.013) after LDKT. Like-
wise, the urine protein/urine creatinine ratio (UP/UC)
was higher in recipients than in donors at baseline (p <
0.001), but not 6 weeks and 6 months after LDKT,
respectively. The triglyceride concentration was also sig-
nificantly higher in recipients than in donors at baseline
(p < 0.001), 6 weeks (p = 0.001) and 6 months (p =
0.011) after LDKT. In contrast, HDL cholesterol concen-
tration was lower in recipients than in donors only at
baseline (p = 0.001), but not 6 weeks and 6 months
after LDKT. The serum concentrations of total and LDL
cholesterol as well as C-reactive protein (CRP) did not
differ at any time between recipients and donors.
Changes in clinical parameters in kidney transplant
donors and recipients after LDKT
In donors the unilateral nephrectomy resulted in a
significant decrease of eGFR within 6 weeks after LDKT
Table 1 Clinical parameters of donors and recipients at baseline, 6 weeks and 6 months after living-donor kidney
transplantation (LDKT)
#
Donors Recipients
N (m/f) 20 (6/14) 20 (14/6)
Age (a) 46 (27-66) 42 (6-77)
Baseline 6 weeks after
LDKT
6 months after
LDKT
Baseline 6 weeks after
LDKT
6 months after
LDKT
eGFR (mL/min per 1.73
m
2)
84 (68-139)
a*** 58 (40-94)
b 57 (40-88)
b 8 (5-16)
A 61 (24-145)
B 63 (19-172)
B
Proteinuria (mg/L) 47 (40-260) *** 40 (40-92) * 44 (40-105) * 544 (42-1943) 175 (37-762) 73 (45-1238)
UP/UC 0.09 (0.04-0.84)
***
0.10 (0.04-0.27) 0.09 (0.04-0.17) 0.78 (0.05-4.43)
A
0.13 (0.06-0.37)
B 0.10 (0.03-1.44)
B
CRP (mg/dL) 0.17 (0.04-2.13) 0.34 (0.03-1.21) 0.28 (0.04-2.72) 0.21 (0.02-1.45) 0.26 (0.02-3.91) 0.22 (0.02-2.57)
Total cholesterol (mg/dL) 182 (141-279) 177 (142-289) 193 (118-269) 182 (126-353)
A 193 (90-291)
AB 191 (134-312)
B
LDL cholesterol (mg/dL) 116 (67-214) 115 (72-211) 126 (68-188) 120 (76-240) 131 (72-222) 126 (72-204)
HDL cholesterol (mg/dL) 58 (39-94) ** 53 (36-90) 56 (35-92) 46 (29-71)
A 52 (36-119)
B 50 (30-78)
B
Trigylcerides (mg/dL) 94 (46-298) *** 124 (64-292) ** 116 (72-397) * 230 (81-671) 207 (81-443) 179 (81-545)
ROH (μg/mL) 0.61 (0.37-0.84)
a***
0.81 (0.41-1.07)
b 0.67 (0.43-1.09)
b 1.46 (0.67-2.25)
A
0.88 (0.38-1.79)
B 1.01 (0.32-1.44)
B
RBP4 (μmol/L) 1.76 (1.08-2.13)
a***
2.11 (1.02-3.38)
b 2.55 (1.19-3.89)
c 6.57 (3.19-8.77)
A
2.80 (1.10-6.38)
B 3.06 (0.99-5.23)
B
TTR (μmol/L) 2.58 (0.96-5.78)
***
3.25 (0.47-5.06) 3.08 (1.91-4.99) 5.60 (2.06-8.37)
A
3.51 (1.58-8.24)
B 4.53 (1.05-6.38)
B
apoRBP4 (%) 0.0 (0.0-8.2)
a*** 8.3 (0.6-13.1)
b 7.6 (0.3-9.6)
b 30.7 (1.2-47.6)
A 12.9 (0.8-23.4)
B 10.2 (0.6-31.0)
B
# Data are presented as median (range). Abbreviations used: CRP, C-reactive protein; eGFR, estimated glomerular filtration rate; HDL, high density lipoprotein;
LDL, low density lipoprotein; LDKT, living-donor kidney transplantation; m/f; male/female; UP/UC, urine protein/urine creatinine ratio. Different superscripts
a, b
and
c indicate significant differences between the different time points for donors. Different superscripts
A and
B indicate significant differences between the
different time points for recipients. Superscripts *, ** and *** indicate significant differences between donors and recipients at the particular time point with * p
< 0.05, ** p < 0.01 and *** p < 0.001.
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Page 2 of 7(p < 0.001) to a median eGFR of 58 mL/min per 1.73
m
2 and approximately 65% of donors revealed a eGFR
below 60 mL/min per 1.73 m
2 corresponding to CKD
stage 3 according the K/DOQI guidelines [17]. Six
months after LDKT the eGFR was still decreased (57
mL/min per 1.73 m
2) in comparison to baseline levels
(84 mL/min per 1.73 m
2, p = 0.001) and approximately
62% of the donors still revealed a eGFR below 60 mL/
min per 1.73 m
2. With regard to the other clinical para-
meters, no differences could be observed between base-
line, 6 weeks and 6 months after LDKT (Table 1).
In allograft recipients transplantation resulted in an
increase of eGFR within 6 weeks (61 mL/min per 1.73
m
2) in comparison to baseline (8 mL/min per 1.73 m
2)
(p < 0.001) and the eGFR remained unchanged in the
recipients for at least 6 months (53 mL/min per 1.73
m
2). In addition, UP/UC was decreased in recipients 6
weeks after kidney transplantation in comparison to
baseline (p = 0.008) and remained decreased also 6
months after transplantation (p = 0.05). Proteinuria
tended to decrease in recipients during the follow-up
period (544 mg/L at baseline to 73 mg/L 6 months after
LDKT); however this tendency was not significant. The
HDL serum concentration increased 6 weeks after trans-
plantation (p = 0.003) in comparison to baseline and
remained increased also 6 months after LDKT (p =
0.013). Finally, there were no changes in the serum con-
centration of CRP, total and LDL cholesterol and trigly-
cerides during the follow-up period in allograft
recipients (Table 1).
Changes in ROH, RBP4, apoRBP4 and TTR in kidney
transplant donors and recipients during follow-up period
Changes in the serum concentration of ROH, RBP4 and
TTR and relative amounts of apoRBP4 before and after
LDKT are shown in Table 1. At baseline, the ROH,
RBP4, apoRBP4 and TTR serum concentrations were
significantly higher in serum of recipients than in serum
of donors (p < 0.001, for all). However, there were no
differences in the parameters between donors and reci-
pients 6 weeks and 6 months after LDKT.
For donors the unilateral nephrectomy resulted in a
significant increase of ROH and RBP4 serum concen-
tration within 6 weeks after LDKT (0.81 μg/mL with p
= 0.004 and 2.11 μmol/L with p < 0.001, respectively)
in comparison to baseline (0.61 μg/mL and 1.76 μmol/
L, respectively). The serum concentrations of ROH
and RBP4 remained increased also 6 months after
LDKT (0.67 μg/mL with p = 0.001 and 2.55 μmol/L
with p < 0.001, respectively). In contrast, the TTR con-
centration did not change significantly in serum of
donors during the follow-up period (baseline 2.58
μmol/L, 6 weeks after LDKT 3.25 μmol/L, and 6
months after LDKT 3.08 μmol/L). With regard to
allograft recipients, the ROH serum concentration
decreased within 6 weeks after LDKT (1.46 μg/mL vs.
0.88 μg/mL, p < 0.001) and remained decreased also 6
months after LDKT (1.01 μg/mL, p < 0.001). In con-
trast, the RBP4 serum concentrations decreased within
6 weeks after LDKT from 6.57 μmol/L at baseline to
2.80 μmol/L (p < 0.001) and remained decreased in
comparison to baseline also 6 months after LDKT
(3.06 μmol/L with p = 0.007). Likewise, the TTR con-
centration in serum of recipients also decreased within
6 weeks after LDKT (3.51 μmol/L, p = 0.001) and
remained decreased also 6 months after LDKT (4.53
μmol/L, p < 0.001) in comparison to baseline (5.60
μmol/L). However, even 6 months after LDKT neither
ROH nor RBP4 nor TTR serum concentrations of reci-
pients decreased to levels comparable to those of
donors at baseline.
With regard to apoRBP4, allograft recipients revealed
a significantly higher relative amount of apoRBP4 than
donors at baseline (p < 0.001), but there were no more
differences 6 weeks as well as 6 months after LDKT.
The unilateral nephrectomy resulted in a significant
increase of the relative amount of apoRBP4 in serum of
donors 6 weeks after LDKT (8.3% vs. 0% at baseline, p
= 0.002), which remained increased for at least 6
months after LDKT (7.6%) in comparison to baseline (p
= 0.002). Vice versa, the relative amount of apoRBP4
decreased in serum of recipients within 6 weeks after
LDKT (12.9% vs. 30.7% at baseline, p = 0.001) and did
not change for at least 6 months after LDKT (10.2%) in
comparison to baseline values (p = 0.001).
Correlation of eGFR with ROH, RBP4, apoRBP4 and TTR in
donors and recipients
To evaluate the association of eGFR with the compo-
nents of the vitamin A transport complex and the rela-
tive amount of apoRBP4 data at baseline, 6 weeks and 6
months after LDKT were pooled for donors and recipi-
ents separately. Non-parametric correlation analyses
were performed for each data set (donors and recipi-
ents) independent from each other and scatter plots as
well as Spearman Rho correlation coefficients (r) are
presented in Figure 1.
For both, donors and allograft recipients, a significant
inverse correlation of eGFR with ROH, RBP4 and TTR
serum concentration as well as relative amounts of
apoRBP4 could be detected. Thereby, donors revealed
particularly strong inverse associations of eGFR with
RBP4 serum concentration (r = -0.502, p < 0.001) and
with apoRBP4 (r = -0.666, p < 0.001). With regard to
allograft recipients, all four parameters were highly
inversely associated with eGFR (p < 0.001), however,
RBP4 serum concentration revealed the strongest corre-
lation (r = -0.860, p < 0.001).
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The kidneys play an important role in the metabolism of
vitamin A and its transport proteins [5,6,18] and it is
well documented that a reduced kidney function due to
acute or chronic renal failure is associated with
increased serum concentrations of ROH, RBP4 and TTR
[5,8,9]. However, very little is known about changes in
the vitamin A transport complex in serum of donors
after LDKT, which represents a sudden loss of kidney
function. Therefore, we investigated the concentrations
of ROH, RBP4 and TTR in serum of donors and the
respective recipients before and after transplantation.
The main clinical consequence of unilateral nephrect-
omy in donors was a decrease in eGFR to approximately
65% of pre-nephrectomy values, which remained
decreased also 6 months after LDKT as also described
by others before [19-21]. In allograft recipients, LDKT
resulted in a general improvement of kidney function,
indicated by an increase of eGFR and decrease of UP/
UC as expected and confirming previous results of
others [22-25].
In donors the ROH and RBP4 serum concentrations
as well as relative amounts of apoRBP4 (RBP4 unbound
to ROH) increased post-nephrectomy and remained
increased during the follow-up period of 6 months. In
addition, it could be demonstrated that the increase of
all three parameters was paralleled by a decrease of the
donor’s eGFR and correlation analysis revealed a signifi-
cant inverse association of eGFR with ROH, RBP4 and
apoRBP4, respectively. These results confirmed and
expanded the observations of Argiles et al. [26], who
reported an increase of ROH and RBP4 serum concen-
tration in donors seven days after LDKT.
The increase of ROH and RBP4 serum concentration
and relative amounts of apoRBP4 is most likely explained
by the essential role of the kidneys in vitamin A metabo-
lism. Under physiological conditions the complex of
ROH, RBP4 and TTR ensures the transport of vitamin A
in the circulation. After the delivery of ROH to the target
tissue, the remaining complex of apoRBP4 and TTR dis-
sociates and the resulting free apoRBP4 is then filtered
and degraded in the kidneys [5,7]. Therefore, a reduction
of kidney function is associated with an increase of
apoRBP4 in serum [27,28], as also seen in the donors of
the present study. In this context, Gerlach and Zile [29]
proposed, that apoRBP4 provides a positive feedback sig-
nal for the hepatic release of holoRBP4 (RBP4 in complex
with ROH), resulting in an increase of ROH and an addi-
tional increase of RBP4 serum concentration. Therefore,
the increased concentrations of ROH and RBP4 in serum
of donors of the present study are most likely attributed
to the decreased kidney function and the resulting
increase of apoRBP4 may in turn trigger the increased
secretion of holoRBP4 from the liver contributing the
increase of ROH and RBP4 serum concentration. The
inverse association of eGFR with ROH, RBP4 and
apoRBP4 in the present study supports this hypothesis
and emphasizes the importance of the kidneys in home-
ostasis of the vitamin A metabolism. However, these
results also indicate that in donors the remaining kidney
function after LDKT does not seem to be adequate to
maintain a normal vitamin A metabolism.
Figure 1 Correlation of retinol, RBP4, apoRBP4 and TTR with
eGFR of donors and recipients represented as pooled values of
measurements at baseline (circles), 6 weeks (squares) and 6
months (triangles) after LDKT
#.
# Data are presented as
Spearman-Rho rank correlation coefficients. Abbreviations used:
eGFR, estimated glomerular filtration rate; LDKT, living-donor kidney
transplantation; RBP4, retinol-binding protein 4; TTR, transthyretin.
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does not seem to be affected by nephrectomy in the pre-
sent study underlines the lesser importance of kidneys
to TTR metabolism [6]. Nevertheless, although not sig-
nificant, the TTR concentration in serum of donors
tended to increase and a longer follow-up period may
might have resulted in a significant increase of TTR as
well.
In view of the vitamin A transport complex, the allo-
graft recipients revealed a reduction of ROH, RBP4, and
TTR serum concentration as well as apoRBP4 within 6
months after LDKT, which is in accordance to results
previously reported by Kelleher et al. [30]. The decrease
in serum concentration of all four compounds was par-
alleled by an increase of eGFR and may be mainly
explained by the restoration of kidney function by
LDKT. Nevertheless, even 6 months after LDKT none
of the components of the vitamin A transport complex
decreased to values comparable to those of donors
before LDKT, which emphasize the incomplete remis-
sion of kidney function with regard to vitamin A meta-
bolism as suggested by Kelleher et al. [30].
The elevated concentrations of ROH and RBP4 in
serum of donors after LDKT raise the question concern-
ing the possible consequences. In principle, kidney
donation has been associated with a low risk for donors
with regard to surgery-associated as well as long-term
complications such as hypertension, CKD, and overall
mortality [1-3,31]. However, evidence is accumulating
that incipient renal failure indicated by a reduced eGFR
is strongly associated with an increased risk for CVD
[4]. In fact, recent data indicate that the long-term risks
associated with living-kidney donation are higher than
previously thought [1] and that there is indeed a paucity
of data concerning cardiovascular risk factors in donors
after LDKT [32]. The situation is exacerbated by the
trend of accepting donors beyond the traditional rigor-
ous inclusion criteria due to the increasing demand for
kidney transplantations [32].
In this context, the increased concentrations of ROH
and RBP4 in serum of donors might contribute to the
risk of CVD, since elevated levels of both parameters
have been associated with CVD [12,13]. Furthermore,
high ROH and RBP4 serum concentrations have been
linked to increased intima-media thickness [14,15] and
RBP4 serum concentration to a higher fat content in
vessel walls and atherosclerotic plaques [14]. The under-
lying mechanisms for these associations remain to be
elucidated, but lipid modulating activities of retinoids
and retinol-binding proteins have been suggested as an
important factor [14,33].
In addition, an elevated serum concentration of RBP4
has been linked to insulin resistance [16] as well as sub-
clinical inflammation [34]. Thus, the nephrectomy-
associated increase of RBP4 serum concentrations may
explain the increased susceptibility of living-kidney
donors for insulin resistance as “described by Shehab-
Eldin et al. [35]. However, since the present study was
an observational study, which primary aim was to ana-
lyze the nephrectomy-associated changes in ROH, RBP4
and TTR in living-kidney donors, the association of the
vitamin A transport complex with CVD and insulin
resistance remains speculative and should be a matter of
future research.
Conclusion
In summary, unilateral nephrectomy resulted in an
increase of ROH and RBP4 serum concentration in liv-
ing kidney donors. This increase remained during the
follow-up period of 6 months, indicating that the capa-
city of the remaining kidney is not adequate to balance
the vitamin A metabolism in donors. Since high levels
of ROH and RBP4 have been associated with an
increased risk of CVD and insulin resistance, future
research should focus on these associations in donors
especially with regard to the baseline risk for CVD and
insulin resistance as well as on potential underlying
mechanisms.
Materials and methods
Subjects and study design
A total of 20 kidney allograft recipients and the respective
donors were recruited at the Medical Department, Divi-
sion of Nephrology and Intensive Care Medicine and the
Department of Pediatric Nephrology, both Charité Univer-
sitätsmedizin Berlin. The group of allograft recipients con-
sisted of 17 adult (12 male and 5 female) and 3 pediatric
(2 male and 1 female) patients. The group of donors com-
prised 6 adult men and 14 adult women. Fifty-five per
cent of the donors were related to the respective recipi-
ents. After transplantation, allograft recipients received
corticosteroids (prednisolone or methylprednisolone (n =
20), tacrolimus (n = 14), mycophenolate mofetil (n = 17),
and basiliximab (n = 2)) and cyclosporine A (n = 5) for
immunosuppression.
Blood samples of donors and recipients were drawn
after an overnight fast 1 to 2 days before LDKT (base-
line) as well as 6 weeks and 6 months after LDKT. The
blood samples were centrifuged for serum preparation
and aliquots were stored at -80°C until assayed. The
study design was approved by the local ethics committee
and written informed consent was obtained before the
study from all participants and parents of the pediatric
patients, respectively.
Measurement of clinical parameters
Blood was taken during routine appointments, creati-
nine, protein, total, LDL and HDL cholesterol,
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tory techniques (and analyzer) in serum. GFR was calcu-
lated based on creatinine levels using the 4-variables-
MDRD equation for adult and Schwartz formula for
pediatric patients [17], respectively.
Determination of ROH, RBP4, TTR, and apoRBP4
For quantification of ROH in serum a modified gradient
reversed-phase high-performance liquid chromatography
(rp-HPLC) system (Waters, Germany) was used after
organic extraction as previously described in detail [36].
RBP4 and TTR serum concentrations were determined
by non-commercial enzyme-linked immunosorbent
assays (ELISA) as described elsewhere [37,38]. For both
ELISA a standard was used containing RBP4 and TTR
obtained from human blood, respectively (Dade Behring,
Germany).
The relative amount of apoRBP4 (% of total RBP4)
was determined by native polyacrylamide gel electro-
phoresis with subsequent immunoblotting as described
by Frey et al. in detail [39].
Statistical analysis
The results are expressed as median and ranges except
otherwise stated. The statistical analysis was performed
using PASW statistics version 17.0. Differences between
donors and recipients were analyzed by Mann-Whitney
U rank sum test. The Friedman test for related variables
was used to test for significant differences between the
different time points (baseline, 6 weeks and 6 months
after LDKT) for donors and recipients separately. If
there was a significant effect, Wilcoxon rank test was
performed to describe differences between two time
points. For calculation of correlation coefficients data at
baseline, 6 weeks and 6 months after LDKT were cumu-
lated for donors and recipients separately and Spear-
man-Rho rank correlation test was performed for both
pooled data sets independent from each other. Values of
P less than 0.05 were considered to be statistically sig-
nificant (two-tailed).
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